Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00863265 · ClinicalTrials.gov registry record · Early Phase 1

Phytosterols, Ezetimibe, and Cholesterol Metabolism

A Early Phase 1 study, sponsored by Washington University School of Medicine.

Completed
Registry status
Early Phase 1
Development phase
22
Enrollment target

NCT00863265 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 22 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00863265, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
Early Phase 1
Development phase
22 participants
Enrollment target

Study Summary

Phytosterols and ezetimibe each reduce intestinal cholesterol absorption by 30-55% but appear to have different mechanisms of action. The investigators' hypothesis is that phytosterols and ezetimibe given together will block cholesterol absorption in an additive fashion. In a randomized, placebo-controlled crossover trial the effects of placebo, ezetimibe treatment and ezetimibe plus phytosterol treatment will be measured.

Interventions

  • OTHER Placebo
  • DRUG Ezetimibe
  • OTHER Phytosterols + ezetimibe

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2009-06
Est. Completion 2010-02
Phase Early Phase 1

What the Registry Record Tells You About NCT00863265

The ClinicalTrials.gov registry entry for NCT00863265 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT00863265 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00863265 about?

NCT00863265 is a clinical study titled "Phytosterols, Ezetimibe, and Cholesterol Metabolism". Phytosterols and ezetimibe each reduce intestinal cholesterol absorption by 30-55% but appear to have different mechanisms of action. The investigators' hypothesis is that phytosterols and ezetimibe given together will block cholesterol absorption in an additive fashion. In a randomized, placebo-con...

What is the current status of trial NCT00863265?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 22 participants. The study started on 2009-06. Estimated completion is 2010-02.

What interventions are being tested in trial NCT00863265?

The interventions under investigation include: Placebo (OTHER), Ezetimibe (DRUG), Phytosterols + ezetimibe (OTHER).

Who is sponsoring clinical trial NCT00863265?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.